Connect with us

Hi, what are you looking for?

Friday, Jun 25, 2021
Mugglehead Magazine
Cannabis & psychedelics industry news based in Vancouver, B.C.
  • Loading stock data...

International

Denmark extends trial for cannabis patients, makes production permanent

Denmark’s parliament ruled its pilot program would continue after it expires at the end of this year

Denmark extends trial for cannabis patients, makes production permanent
Image via Aurora Nordic, a subsidiary of Aurora Cannabis Inc

Danish patients will be able to access medical cannabis for at least another four years, and companies in the country producing the plant for medical purposes can operate permanently.

Late Tuesday, a broad majority of parties voted in Danish parliament to continue a trial scheme for medical cannabis access, which expires at the end of the year.

The ruling Social Democrats, the Liberals, the Danish People’s Party, the Socialist People’s Party, the Unity List, the New Bourgeois, Liberal Alliance, the Alternative, the Christian Democrats and the Free Greens all voted in favour.

Denmark’s curious division of production and access will continue, as foreign firms will provide domestic supply via import, and companies within Danish borders ship medical weed to other European markets.

The current trial will expire at the end of 2021, but its continuation is mandated by law thereafter, according to the Danish Ministry of Health The government will submit bills this fall for adoption by the end of the year.

Only a select few Good Manufacturing Practices-certified producers are approved to supply Denmark’s medical patients, including Netherlands-based Bedrocan, as well as Canadian firms Aurora Cannabis Inc. (TSX and NYSE: ACB) and MediPharm Labs Corp. (TSX: LABS).

Read more: MediPharm enters Denmark’s medical cannabis market

Denmark opened medical cannabis access for patients in 2018 as part of a four-year pilot program. Its purpose is to offer patients with legal, safe products and provide national health authorities with patient data.

That information was to be analyzed to understand usage and efficacy at the end of the trial period to consider establishing a permanent medical market, but a permanent domestic plan hasn’t been mentioned yet.

The program is only eligible for patients suffering from multiple sclerosis, spinal cord damage, cancer and neuropathic pain.

 

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

nick@mugglehead.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can

News

Cannabis will be treated like alcohol under the company's policy changes

Enforcement

The legislation's steep penalties and confusing rules are a step backward to populations that have used cannabis traditionally for centuries

Canada

As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices